Ownership and insider activity for Grace Therapeutics, Inc. (GRCE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage.
Price
| Price | $2.14 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-09 | Opaleye Management Inc. | P-Purchase | 5,836 | $12K |
| 2026-09-08 | Opaleye Management Inc. | P-Purchase | 9,393 | $20K |
| 2026-09-09 | Kohli Prashant | P-Purchase | 100,000 | $214K |
| 2026-08-28 | Kumar Amresh | A-Award | 35,760 | $76K |
| 2026-08-28 | Kohli Prashant | A-Award | 267,160 | $566K |
| 2026-08-28 | Macdonald R. Loch | A-Award | 54,690 | $116K |
| 2026-08-28 | DelAversano Robert J | A-Award | 33,660 | $71K |
| 2026-08-14 | Opaleye Management Inc. | P-Purchase | 11,608 | $24K |
| 2026-01-08 | Kavuru Vimal | A-Award | 10,000 | $38K |
| 2026-01-08 | Kottayil George | A-Award | 10,000 | $38K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 0 | $6.4M | $16.9M | $20.1M | $64.0M | $30.3M | $27.9M | $23.0M | $22.1M | $17.0M |
| Short-term Investments | 0 | 0 | $8.9M | 0 | $12.3M | $13.3M | $15000 | 0 | 0 | 0 |
| Receivables | $206167 | $759260 | $1.6M | $771811 | $665810 | $548000 | $802000 | $722000 | $126000 | $20000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $10.2M | $7.4M | $28.0M | $22.6M | $78.4M | $45.5M | $29.3M | $24.0M | $22.7M | $17.4M |
| Property, Plant & Equipment | $2.9M | $2.2M | $2.1M | $2.9M | $108037 | $315000 | $567000 | $24000 | $15000 | $8000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | $13.0M | $8.1M | $8.1M | $8.1M | $8.1M |
| Intangible Assets | $12.4M | $7.8M | $6.4M | $6.0M | 0 | $69.8M | $41.1M | $41.1M | $41.1M | $41.1M |
| Total Assets | $25.5M | $17.8M | $36.9M | $32.3M | $78.5M | $128.6M | $79.1M | $73.3M | $72.0M | $66.7M |
| Accounts Payable | 0 | $2.6M | $3.0M | $2.4M | $144468 | $3.2M | $1.2M | $1.0M | $601000 | $702000 |
| Short-term Debt | 0 | 0 | $1.4M | $121567 | $108037 | $104000 | $75000 | 0 | 0 | 0 |
| Total Current Liabilities | $2.1M | $5.2M | $13.7M | $10.5M | $2.0M | $3.3M | $3.4M | $1.7M | $1.9M | $2.1M |
| Long-term Debt | $1.4M | $1.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $3.8M | $11.4M | $25.9M | $13.9M | $8.5M | $20.4M | $11.2M | $11.6M | $5.4M | $2.8M |
| Retained Earnings | -$50.9M | -$56.0M | -$100.8M | -$178.6M | -$183.4M | -$155.8M | -$198.3M | -$211.1M | -$220.7M | -$228.5M |
| Total Equity | $21.7M | $6.4M | $11.0M | $18.4M | $69.9M | $108.3M | $68.0M | $61.7M | $66.6M | $63.9M |
| Total Debt | $1.4M | $1.2M | $1.4M | $207795 | $108037 | $295000 | $485000 | 0 | 0 | 0 |
| Net Debt | -$8.4M | -$5.1M | -$24.4M | -$19.9M | -$76.2M | -$43.4M | -$27.4M | -$23.0M | -$22.1M | -$17.0M |
| Working Capital | $8.1M | $2.2M | $14.3M | $12.1M | $76.4M | $42.3M | $25.9M | $22.3M | $20.8M | $15.2M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 11.47 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 11.56 |
Profitability
| Return on Equity | -35.78% |
| Return on Invested Capital | -48.75% |
| Return on Assets | -42.84% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABVC · ATNM · CALC · LTRN · LVTX · OKUR · PDSB
Explore sector: Healthcare · Biotechnology
More sections of GRCE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks